Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Immunogen Inc (IMGN)  
$31.23 0.00 (0.00%) as of 4:30 Thu 2/8


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 264,900,000
Market Cap: 8.27(B)
Last Volume: 49,305,461 Avg Vol: 5,854,790
52 Week Range: $4.32 - $31.23
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  606
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 39,348 1,060,446 4,785,085 4,785,085
Total Sell Value $1,152,494 $23,992,060 $86,338,289 $86,338,289
Total People Sold 4 5 5 5
Total Sell Transactions 4 17 26 26
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 257
  Page 8 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Barrows Craig Executive VP, General Counsel   •       –      –    2017-09-15 4 OE $4.50 $135,000 D/D 30,000 66,500     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2017-09-13 4/A S $6.95 $101,404 D/D (14,600) 176,900     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2017-09-13 4/A OE $4.50 $90,000 D/D 20,000 191,500     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2017-09-13 4 S $7.00 $10,500 D/D (1,500) 161,800     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2017-09-13 4 S $6.95 $101,404 D/D (14,600) 36,500     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2017-09-13 4 OE $4.50 $90,000 D/D 20,000 51,100     -
   Ryll Thomas VP, Technical OperationsOffice   •       –      –    2017-03-29 3 IO $0.00 $0 D/D 0 108,100     -
   Williams Peter J. VP, Business Development   •       –      –    2017-02-23 4 A $2.57 $5,140 D/D 2,000 50,620     -
   Williams Peter J. VP, Business Development   •       –      –    2017-02-21 4 A $2.47 $120,091 D/D 48,620 48,620     -
   Barrows Craig Vice-President,General Counsel   •       –      –    2017-02-21 4 A $2.47 $346,788 D/D 140,400 171,500     -
   Gregory Richard J. Executive VP & CSO   •       –      –    2017-01-08 4 AS $6.64 $19,287 D/D (2,904) 273,577     -
   Goldberg Mark Alan Director   –       •      –    2016-12-15 4 B $1.80 $36,000 D/D 20,000 23,800 2.39     -
   Berkenblit Anna VP & Chief Medical OfficerOffi   •       –      –    2016-12-09 3 IO $0.00 $0 D/D 0 6,000     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2016-11-08 4 B $1.83 $45,738 D/D 25,000 100,100 2.81     -
   Gregory Richard J. Executive VP & CSO   •       –      –    2016-11-02 4 B $1.78 $29,598 D/D 16,600 39,231 2.74     -
   Barrows Craig Vice-President,General Counsel   •       –      –    2016-11-02 4 B $1.71 $17,075 D/D 10,000 31,100 2.74     -
   Johnston David Brannon Chief Financial Officer   •       –      –    2016-11-02 4 B $1.70 $16,981 D/D 10,000 10,000 2.74     -
   Lambert John Executive Vice President   •       –      –    2016-11-02 4 B $1.69 $4,676 D/D 2,775 120,521 2.66     -
   Junius Daniel M Director   –       •      –    2016-06-02 4 OE $3.19 $86,401 D/D 27,085 196,700     -
   Enyedy Mark J Chief Executive OfficerOfficer   •       •      –    2016-05-16 3 IO $0.00 $0 D/D 0 75,100     -
   Lambert John Executive Vice President   •       –      –    2016-02-26 4 OE $3.19 $52,796 D/D 10,889 117,746     -
   Lambert John Executive Vice President   •       –      –    2016-02-01 4 AS $8.22 $31,971 D/D (3,889) 106,857     -
   Lambert John Executive Vice President   •       –      –    2016-02-01 4 OE $3.19 $12,406 D/D 3,889 110,746     -
   Gregory Richard J. Executive VP & CSO   •       –      –    2016-01-08 4 AS $11.10 $26,305 D/D (2,369) 22,631     -
   Junius Daniel M Chief Executive Officer   •       •      –    2016-01-04 4 AS $13.17 $71,349 D/D (5,416) 169,615     -
  257 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us